A study by El Kramani et al. [176] determined FSCN1 levels in with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cases in comparison to controls using enzyme-linked immunosorbent assay in the plasma and leukocytes and found FSCN1 expression significantly elevated in AML but not in ALL cases, suggesting FSCN1 as a potential biomarker for AML. The gene discussed is FSCN1; the disease is acute lymphoblastic leukemia.